Baker Tilly Wealth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Baker Tilly Wealth Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,896	Closed	-$643K	–	580
2023 Q1	$643K	Sell	5,896 -5,159	-47%	-$570K	0.07%	277
2022 Q4	$1.26M	Sell	11,055 -4,405	-28%	-$366K	0.15%	155
2022 Q3	$957K	Sell	15,460 -821	-5%	-$57.4K	0.13%	173
2022 Q2	$1.3M	Buy	16,281 +2,048	+14%	+$194K	0.17%	129
2022 Q1	$1.5M	Sell	14,233 -33	-0.2%	-$3.22K	0.17%	128
2021 Q4	$1.54M	Buy	14,266 +693	+5%	+$75.6K	0.17%	129
2021 Q3	$1.49M	Buy	13,573 +6,183	+84%	+$642K	0.2%	99
2021 Q2	$692K	Buy	7,390 +1,036	+16%	+$95.3K	0.11%	204
2021 Q1	$585K	Buy	6,354 +780	+14%	+$65.8K	0.12%	208
2020 Q4	$408K	Buy	+5,574	New	+$414K	0.13%	177

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Baker Tilly Wealth Management's HZNP Position: Q2 2023 in Review

Baker Tilly Wealth Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 5,896 shares — an estimated $643K sold.

Baker Tilly Wealth Management first reported a position in HZNP in Q4 2020 and held it in 10 quarters. The position peaked at $1.54M in Q4 2021. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Baker Tilly Wealth Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Baker Tilly Wealth Management sold 5,896 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $643K.
Baker Tilly Wealth Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 10 quarters.
Baker Tilly Wealth Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.54M in Q4 2021.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Baker Tilly Wealth Management's 13F filing for Q2 2023, filed 20 Jul 2023.